ABSTRACT
CD4' Th cell subsets and three CD81 T, cell subsets. The frequencies and absolute numbers of these five populations were measured in patients with active and inactive MS and were compared with those in healthy age-matched controls and in patients with other neurologic diseases. A high frequency of patients with active MS (80%) had a selective reduction of one Th subset (CD4' Lp220') compared with normal controls (P < 0.001) or patients with inactive MS (P < 0.001). Three patients examined sequentially had a further loss of the Lp220+ Th subset as disease activity progressed. The proportion of two T, subsets was also abnormal in patients with active MS, but this defect was not restricted to that group. Total Th and T5 cell frequencies and Th/TS ratios were not significantly different between patient and normal control groups. Thus, two-color analysis of T-cell subsets may be a more sensitive indicator than conventional single-marker assays of abnormal immune status in MS patients.
Recent studies have suggested that multiple sclerosis (MS) may be a disorder of immune regulation in which effector and regulatory T-cell populations are altered (1) (2) (3) (4) (5) . Several studies have found a reduction in both the number and activity of T suppressor/cytotoxic (Tj) cells in MS patients that may correlate with disease activity (6, 7) . The ratio of T helper/inducer (Th) cells to T. cells (Th/T, ratio) has been used extensively to assess abnormalities in MS patients, with varying results. In several studies, MS patients with active disease were found to have a greater frequency of abnormal Th/Ts ratios (6, 7) , but this is not a consistent finding (8, 9) .
No clear consensus has been reached on the significance of changes in lymphocyte subsets associated with MS.
Improvements in multiparametric fluorescence-activated cell sorter (FACS) methods have made it possible to define lymphocyte subsets more readily (10) (11) (12) . Subpopulations of B cells (13, 14) , natural killer (NK) cells (15) , and regulatory T cells (16) can be quantitated based on the relative expression of two or more cell-surface markers. This approach has been used to define abnormal lymphocyte subsets in immunodeficient and autoimmune mice (14, 17) . Using pairs of monoclonal antibodies (mAb) to the CD4 and CD8 T-cell subset markers and to the common leukocyte antigens Lp220 and Lp95-150, we were able to define five distinct T-cell subsets in this study. A comparison between MS patients and controls revealed that patients with active MS have a selective loss of one Th subset (CD4' Lp220). This CD4' Th subset did not possess the majority of helper function for B-cell antibody production. The frequency of this subset decreased in three patients as disease activity increased, suggesting that loss of Lp220' CD4' cells may relate to a worsening clinical status. One Ts subset was depleted in active MS patients, but this defect was also seen in other neurologic diseases. No differences in conventional singleparameter Th/T, ratios were evident, suggesting that twocolor FACS analysis may be a more sensitive method for monitoring abnormal immune status.
METHODS
Patients. All patients with MS satisfied the Schumacher criteria (18) for clinically definite disease. Those with inactive MS had been clinically stable for 6 months or longer, with an overall disability rating of <5 on the Kurtzke disability status scale (19) . Those with active MS had acute exacerbations, defined as the report of new symptoms persisting >24 hr, that correlated with an objective change in the standard neurologic examination. Evanescent symptoms involving sensory or motor modalities that could not be objectively verified were not considered to represent a true exacerbation. Blood was obtained within 5 days of the onset of new symptoms. Normal control subjects consisted of hospital and laboratory personnel. Neurologic disease controls consisted of the following patient groups: Parkinson disease (n = 8), amyotropic lateral sclerosis (n = 3), myasthenia gravis (n = 2), Alzheimer disease (n = 2), cerebral vascular accident (n = 2), alcoholic or diabetic neuropathy (n = 3), transient ischemic attack (n = 2), and essential tremors (n = 6). The MS groups consisted of 15 patients with active disease and 32 stable patients. Three patients with active MS were tested serially.
The control populations consisted of 58 age-matched healthy donors and 28 patients with other neurologic diseases. Patients and healthy donors were not treated with steroids for at least 1 month before analysis of lymphocytes and no patient had been on immunosuppressive drugs within 1 year.
Cell Preparations. Human peripheral blood lymphocytes (PBL) were isolated from heparinized venous blood by means of Ficoll-Hypaque density gradient centrifugation (Litton Proc. Natl. Acad. Sci. USA 82 (1985) Bionetics). In some experiments, unfractionated PBL were adhered to plastic for 2 hr at 370C to remove monocytes and were then separated into E rosette-positive (E+) and E rosette-negative (E-) populations with 10% AET-treated sheep erythrocytes as described (20) . The E-fraction was used without further manipulation as a source of enriched B cells.
mAb. The following mAb were used in this study: the 60.3 mAb (IgG2a/k) to a common leukocyte cell-surface antigen family (Lp95-150) related to the LFA-1 complex and involved in a cell activation pathway (21) ; the 3AC5 mAb (IgG2a/k), which precipitates a 220,000-Da peptide (Lp220) that is part ofthe T200 complex (22) ; the G17-2 mAb (IgGl/k) to the CD4 (T4) Tp55 helper T-cell-associated antigen (23) ; the G10-1 mAb (IgG2a/k) to the CD8 (T8) Tp32 suppressor T-cellassociated antigen (23) ; the G3-7 mAb (IgG1/k) to the CD7 (3A1) Tp41 pan T-cell antigen (23) ; and Leu8 (BectonDickinson), a marker expressed on leukocyte subsets (12) .
Conjugation of mAb with Fluorescein 5-Isothiocyanate (FITC) and R-Phycoerythrin (PE). mAb were conjugated with fluorescein by using FITC (24) or with the phycobiliprotein PE derived from the red algae Porphyra yezoensis by using the heterobifunctional cross-linker SPDP as described (25, 26 (Fig. 1A) . Every four to five dots represent a doubling of fluorescence intensity. Because only directly conjugated antibodies of high affinity were used, fluorescence intensity is a good indicator of density of the markers on cells (22, 26 with abnormal and normal ratios in each group were assessed by x2 analysis.
Detection of in Vitro Secretion of IgG. To determine the effect of subpopulations of the CD4+ subsets on the secretion ofIgG by stimulated B cells, 5 x 104 sorted CD4+ Lp220+ and CD4+ Lp220-cell subsets were added to 5 x 104 Emononuclear cells in a vol of 0.5 ml of pokeweed mitogen (Difco) at a final dilution of 1:100. Quadruplicate cultures were set up for each group. On day 7, supernatants were harvested, and IgG secretion into supernatants was determined by solid-phase immunoassay in which purified goat anti-human IgG (Qualex) was used as described (28) .
RESULTS
To determine which pairs of mAb could best divide T-cell subsets, we tested >50 two-color combinations on normal blood lymphocytes before screening MS patients for T-cell abnormalities. When blc lymphocytes were stained with a PE (red)-conjugated anti-CD4 (T4) antibody (Fig. 1B) , '60% of total lymphocytes were stained. mAb to the Lp220 common leukocyte antigen clearly divided CD4+ Th cells into two subpopulations (Fig. 1D ): an Lp220+ subset and an Lp220-subset. The cutoff point for Lp220-cells was determined by staining peripheral cells with anti-CD4 mAb alone (Fig. 1B) . Most, but not all, of the CD4-cells were also Lp220+ (Fig. 1D ). Approximately 50% of CD4+ cells expressed the Lp220 molecule, which is distinct from Leu8+ (12) or CD7+ (26) (29) .
We compared the frequency of these five subsets in patients with active and inactive MS with the frequency in healthy age-matched controls and in patients with other neurologic diseases ( Table 1 ). The frequency of total CD4' Th cells did not differ between groups. However, as illustrated in Fig. 1 , a comparison between patients with active MS (Fig. iF) and healthy individuals (Fig. ID) revealed that active MS patients had a low frequency of the Lp220' Th subset. The mean percentage of Lp220' Th cells in patients with active MS (14.4%) was significantly less than that of patients with inactive MS (28.2%) or that of healthy controls (29%) (P < 0.001).
When ratios of Lp220-Th cells to Lp220' Th cells (Th ratio) were calculated, the differences between active MS and control groups were even more evident. As shown in Fig. 2 and summarized in Table 1 In subsequent studies, we attempted to define the function ofthe Lp220 molecule and the Lp220' Th cell subset depleted during acute exacerbations. The CD4' population is known to contain Th cells that augment B-cell immunoglobulin production (30), so it was important to determine whether T-cell help for antibody production was restricted to Lp220' CD4' or Lp220-CD4' subpopulations. Unfractionated T cells or Lp220' CD4' T cells or Lp220-CD4' T cells isolated by cell sorting were mixed with autologous B cells and cultured in vitro with pokeweed mitogen; after 7 days, total IgG production was measured (Table 2) . Neither B cells, unfractionated T cells, nor the cell-sorter fractionated subsets alone produced significant IgG. However, in a series of experiments the helper effect of Lp220-CD41 cells was consistently 2 to 3 times greater than that ofthe Lp220' CD4' subset. When equal numbers of Lp220' and Lp220-were mixed together and cultured with autologous B cells, the helper activity was less than with Lp220-CD4' T cells alone. the possibility that the lack of helper activity in the sorted Lp220+ CD41 subset was due to a blocking effect of the anti-p220 mAb.
A second series of experiments suggested that the Lp220 molecule may play a role in T-cell activation. First, when T cells were fractionated into buoyant and dense fractions by using Percoll gradients, the proportion of CD41 cells that were Lp220' was highest in dense fractions (46% of total CD41 cells) and lowest in buoyant fractions (12.5% of total CD4 cells). Second, when T cells were stimulated to proliferate, the expression of Lp220 molecule decreased as interleukin 2 receptor expression increased (31) . The role the Lp220 molecule plays in promoting interleukin 2-dependent T-cell activation is described in detail elsewhere (31) . Thus, the Th cells depleted in active MS express the Lp220 molecule that is found principally on dense Th cells and is involved in T-cell activation.
Several previous studies have reported that CD8' T, cells are selectively depleted in patients with active MS (6) . In this series of MS patients, we detected a depletion of a subset of CD8' cells, but this depletion was also seen in other control groups (Table 1) . Of the three T, subsets that were measured (Fig. 1C) , the CD8dull cells, thought to contain the NK cell subset (29), were not statistically different between groups 
DISCUSSION
Using two-color FACS analysis of PBL, we have identified two Th and three T, cell subsets. These T-cell subsets were measured in patients with MS during clinically active and inactive stages of disease. We have found that a high frequency of patients with active MS have a selective depletion of one Th subset (Lp220+ CD4+). Both the frequency and absolute levels of this subset were greatly depleted in patients with active disease. In addition, when three patients with active MS were tested serially, the levels of Lp220+ Th cells in peripheral blood decreased as disease activity increased. Our observation that MS patients with acute exacerbations have the lowest levels of Lp220+ Th cells (Fig. 3) supports this possibility. A longitudinal study will help determine more precisely the kinetic relation of Lp220+
Th cell depletion to the onset of exacerbation.
The difference between patients with active MS and control groups was also clearly evident when the proportion of Lp220-to Lp220+ Th cells was expressed as a "Th subset" ratio. (33) . In addition, a selective depletion of Lp220' CD4' cells has been observed during acute EAE in macaques (unpublished observations). The implication is that CD4' cells may be leaving the blood and entering the central nervous system with sequestration or trapping of these cells in the brain. EAE can be induced by adoptively transferring myelin-basic protein-specific T-cell clones into mice (34); recently, Waldor and coworkers have shown that a rat mAb L3T4, specific for the CD4 homologue in mice, when inoculated in vivo cannot only prevent the development of EAE, but can also cure mice that already have EAE (35) . These results strongly suggest that Th cells play an active role in this neurologic disease and presumably in MS as well.
Alternatively, the depletion of Lp220 CD4' cells could be due to the selective lysis of this T-cell subset. The absolute decrease of Th cells seen in MS is reminiscent of the Th cell depletion observed in patients with acquired immunodeficiency syndrome (AIDS) (36) and chronic lymphadenopathies (37) . In patients with chronic lymphadenopathy, a subset of CD4' cells (Leu8+) are depleted (38) , and, as with MS patients, the depleted subset lacks Th activity.
The precise function of the Lp220' Th cells is not yet known. It is clear that the Lp220-Th cells, and not the Lp220' Th cells possess the majority of helper activity for B-cell IgG production ( Table 2 ). The most likely possibility is that Lp220' and Lp220-Th cells differ in their state of activation. Expression of the Lp220 molecule decreases as T cells are activated, and the Lp220 molecule itself apparently plays a role in lymphocyte activation (31) . Antibody to the Lp220 molecule rapidly increases the expression of interleukin 2 receptors on activated T cells and promotes T-cell proliferation in interleukin 2-dependent T-cell proliferation assays (36) . The loss of a Lp220+ CD4+ T-cell subset in active MS could explain why some MS patients have defective T-cell proliferative responses (39) . 
